Fosun Pharma has acquired China rights to an anti-MET monoclonal antibody developed by Kolltan Pharma, a clinical stage New Haven, Connecticut biotech. In preclinical studies, KTN0216 is being tested against neuroblastoma, a form of brain cancer. Kolltan expects KTN0216 will prove to be effective against HGF-dependent and MET-amplified tumors. According to Kolltan’s website, KTN0216 is about to begin IND-enabling studies. Financial details of the agreement were not disclosed.
